BREAKING: Inside Thrive… | Sourcery Newsletter Summary

1. Key Themes

Theme 1: Healthcare is a massive, underperforming market, and AI may be the first tool large enough to change outcomes

The system spends enormously with no longevity gain

"For the last 10 years, we've spent about 40 trillion on healthcare. We have not moved our life expectancy an inch. And if that is not an indictment of the failure of the healthcare system, I don't know what is."

Supporting data from the article: "US healthcare spending passed $5T in 2024, about 18% of GDP. CMS projects spending will reach $9T by 2034," and healthcare is "the largest line item in the federal budget at 6x defense."

Demand is rising while supply shrinks

"The US faces a projected shortage of 86,000 doctors by 2036. By 2034, Americans over 65 will outnumber those under 18, and the CDC estimates 3 in 4 Americans already have a chronic condition."

The "AGI-pilled" investor should be long healthcare

"If you're truly AGI-pilled, as they say, you should be actually long healthcare."

"Our problems haven't gotten smaller. The tools we have have gotten bigger."

Ayogu also frames it as a trade-off: "If someone told me, 'Hey, we're gonna spend a trillion more on healthcare this year, but everyone gets to live to 100,' I'll take that trade any day of the week."

Theme 2: AI drug discovery is moving from promise to clinic, and bottlenecks will shift downstream

Isomorphic Labs is the flagship bet

"In May 2026, Thrive led a $2.1B Series B to scale IsoDDE, Isomorphic's drug design engine, toward the clinic."

Performance claims from the article: "IsoDDE more than doubles AlphaFold 3's accuracy on a hard protein-ligand benchmark, with a 50% success rate in the hardest bin and 17 wins where AlphaFold 3 failed. It performs 2.3x better on antibody-antigen prediction."

The prize is changing the success rate

"Rather than having a 5% success rate, I can have a 60% success rate. That radically changes the things I'm willing to do all the way throughout the process."

Bottlenecks migrate to testing, trials and manufacturing

"If we're going to make this go from a 10-year process to a 4-year process, it both means that we need to get better at our molecular design. We have to get better at our in vitro testing. We have to get better at our in vivo testing."

The article notes "Ayogu expects bottlenecks to move into clinical trials and manufacturing as discovery speeds up," and that the next modeling problem is predicting "a drug's effects and side effects in cells, animals and people, which requires generating new training data."

Theme 3: AI adoption among clinicians is already mainstream, led by products doctors genuinely love

Physician usage is surging

"The AMA reports 72% of physicians now use at least one AI use case, up from 48% in 2024. More than half of health systems that can quantify AI report 2x+ ROI, with the strongest returns in clinical documentation, denial prediction, coding and ambient listening."

OpenEvidence's penetration is extraordinary

"OpenEvidence is used by 65% of US doctors, with about 650,000 physicians active across roughly 27M clinical encounters as of April 2026. Epic, which has been in the market for nearly 50 years, sits at 44%." Queries "grew 10x in 17 months to 1M per day."

"I've never heard doctors rave about a clinical tool."

Adoption sequence: back office, front office, in office

"Revenue cycle management in the back office moved first. Voice agents for scheduling and patient follow-up came next in the front office. In office, ambient scribes and OpenEvidence lead adoption."

Theme 4: Thrive's thesis is "bilingual" companies that pair world-class technology with world-class clinical or scientific talent

The "bilingual" filter

"We want companies that are bilingual. So we want companies that are truly the best at both of what they do. They speak 2 languages fluently."

Talent density compounds

At Isomorphic, "the AI researchers come from the DeepMind lineage and are held to the same bar as Anthropic and OpenAI," while chemists and biologists "match the talent at Lilly, Pfizer, the Broad Institute and the Wyss Institute." At Neuralink, hardware engineers work "at the level of SpaceX and Tesla Optimus" alongside practicing neurosurgeons.

"People who are truly N of 1 want to work with other N of 1 people."

Clinical background as an edge in sourcing

Ayogu says "Doctors he trained with in residency were the ones who first recommended OpenEvidence to him," and:

"My clinician hat is what let me actually see, oh wow, this is a differentiated product."

Theme 5: The science of personalized medicine is arriving faster than the infrastructure to deliver it

N-of-1 therapies work but cost too much

Baby KJ received a custom gene-editing therapy for a rare ammonia-processing disorder and "is now a toddler who walks and talks. The treatment cost about $1.5M to make and deliver."

"The science has gotten there in so many of these things, but the bottleneck, again, it shifts."

"How do we make it so it's not a million and a half to develop this? What infrastructure needs to exist to make that more scalable and more repeatable and cheaper?"

Personalized cancer vaccines show efficacy

"Moderna and Merck are pairing a personalized mRNA cancer vaccine with Keytruda for melanoma... In trials, patients who received it were about 50% less likely to see their cancer return."

Access is its own investment category

"Thrive's portfolio also targets access to existing breakthroughs," citing Nourish (nutrition counseling, "higher weight loss and GLP-1 persistence") and Rightway (pharmacy benefits and "access to novel drugs").

2. Contrarian Perspectives

Neuralink may be a more interesting company than SpaceX

"I actually think Neuralink is a more interesting company than SpaceX. Hot take. In a lot of ways, if anything, the brain is vaster than space."

Evidence: the implant "reads neurons through more than 1,000 electrodes on microscopic threads, and Neuralink built its own surgical robot to implant them," patients "now use the implant to drive wheelchairs and operate robotic arms," and a separate trial targets speech restoration. The article also notes "Neuralink created the brain-computer interface category, and its lead in recruiting top talent has compounded since."

Healthcare, not software, may host AI's most important breakthroughs

"Coding is the use case that Silicon Valley cares the most about. Healthcare is the use case that Main Street cares most about."

Evidence: an OpenAI clinical copilot in a Penda Health study "cut diagnostic errors 16% and treatment errors 13%," and OpenAI with Boston Children's and Harvard hospitals "reached new diagnoses for about 20" of roughly 300 unsolved pediatric cases. Ayogu's own testing: "These are cases that neither me nor my colleagues, some of the best doctors out there, maybe we would get it right 2 times out of 10. And OpenAI and the o1 was batting a 10 out of 10."

A new health insurer can be built, against received wisdom

"The last health insurer that was created was in 1977. That was UnitedHealthcare. You can't just make a new health insurer. It's too hard. It takes too much scale. It takes too much capital."

Evidence: Ayogu himself told Oscar's founders "it could not be done," yet Oscar "reached 3.17M members by the end of Q1 2026, up 56% year over year," with Q1 revenue up 53% to $4.65B, net income of $679M, and an operating margin of 15.2% "compared with 3.73% at Centene." Over two years the stock is up 56% "while a basket of public insurers is down 14%," after trading near $2 in December 2022 (down ~95%) when Thrive held its position.

3. Companies Identified

Isomorphic Labs

Description: AI drug design company founded by Nobel laureate Demis Hassabis, built on the DeepMind lineage.
Why mentioned: Thrive's flagship AI-drug-discovery investment; $2.1B Series B led by Thrive in May 2026.
Quotes: "Isomorphic Labs, founded by Nobel laureate Demis Hassabis, is building AI models to compress that process." / "Pharma partners include Novartis, Lilly and J&J, with work spanning small molecules, antibodies, peptides, molecular glues and biologics."

Neuralink

Description: Brain-computer interface company.
Why mentioned: Category creator with elite multidisciplinary talent; restores independence to paralyzed patients.
Quotes: "Neuralink's implant lets patients with ALS or paralysis control a computer with their minds." / "I've never met a company before that insourced their own pathology lab."

OpenEvidence

Description: AI clinical decision-support tool for physicians, founded by Daniel Nadler.
Why mentioned: Fastest-adopted clinical tool; surpassed Epic in physician reach.
Quotes: "OpenEvidence is used by 65% of US doctors" / "After testing the product himself, Ayogu drove to founder Daniel Nadler's home in Malibu, and Thrive invested that day."

Oscar Health

Description: Consumer-centric health insurer; Thrive's first investment, now a public Fortune 500 company.
Why mentioned: Case study in conviction and in building on the ACA marketplaces with its own tech stack.
Quotes: "Oscar reached 3.17M members by the end of Q1 2026, up 56% year over year and one of the largest ACA plans." / "Oscar launched Oswell, an AI health agent that handles medications, test results, drug interactions, refills and appointment prep."

Cadence

Description: Remote patient monitoring for chronic disease (Thrive incubation).
Why mentioned: Strong published outcomes and Medicare savings.
Quotes: "Published results show a 25% reduction in hospitalizations, an 80%+ increase in blood pressure control and nearly a full point reduction in A1C. Cadence saves Medicare $2.5M every week." / "If you asked a 10-year-old, 'What should healthcare be like?' I feel like Cadence is what they would draw out."

Fortell

Description: AI-powered hearing aid maker, founded by former Butterfly Network engineer Matt de Jonge.
Why mentioned: Breakout product that "broke the rating scale."
Quotes: "Fortell, founded by former Butterfly Network hardware engineer Matt de Jonge, built a custom chip taped out at TSMC and uses AI to separate speech from background noise." / "4.5 was their highest rating that a hearing aid had ever gotten on their 5-point scale. Fortell recently did it and got a 6."

OpenAI

Description: Frontier AI lab; Thrive portfolio company.
Why mentioned: Moving into healthcare; clinical copilot results; Thrive helped open the door to health leaders.
Quotes: "Hundreds of millions of people ask ChatGPT health questions every week." / "Ayogu organized meetings between OpenAI leadership and top biotech, payer and health system CEOs."

Eli Lilly

Description: Pharma company; first healthcare company to reach a $1T valuation.
Why mentioned: Model for combining science with manufacturing scale and care delivery.
Quotes: "Lilly became the first by pairing better science with manufacturing scale during GLP-1 shortages and moving into care delivery with LillyDirect."

Cityblock Health

Description: Integrated medical, behavioral and social care for high-cost, high-need populations (Thrive portfolio).
Why mentioned: Ayogu's early career; scaled from startup to national care infrastructure.
Quotes: "Cityblock grew from an early-stage startup into national care infrastructure."

Amazon Pharmacy / Amazon Clinic / Amazon Health

Description: Amazon's healthcare businesses, where Ayogu held leadership roles.
Why mentioned: Ayogu's operating background and lessons on trust.
Quotes: "Amazon then acquired One Medical, and the 3 businesses together became Amazon Health." / "People trust you with their medications. Will they trust you with their care delivery?"

Nourish

Description: Nutrition counseling for chronic disease.
Why mentioned: Improves access to GLP-1 benefits.
Quotes: "Nourish provides nutrition counseling for chronic disease, reports higher weight loss and GLP-1 persistence for patients on its platform, and raised a $100M Series C."

Rightway

Description: Pharmacy benefits company (Thrive incubation, valued over $1B).
Why mentioned: Access to novel drugs.
Quotes: "Rightway works on pharmacy benefits and access to novel drugs."

Other Thrive healthcare portfolio companies

Nudge, Formation Bio, Chai Discovery, Cedar, Abby Care: named as part of the portfolio.
Quote: "The health portfolio includes Isomorphic Labs, Neuralink, Nudge, Fortell, Oscar Health, OpenEvidence, Formation Bio, Chai Discovery, OpenAI, Rightway, Cadence, Nourish and Abby Care."

Moderna / Merck

Description: Pharma partners on a personalized mRNA cancer vaccine paired with Keytruda.
Why mentioned: Evidence that personalized medicine is reaching patients.
Quotes: "Each vaccine is built from the sequenced genome of the patient's own tumor and trains the immune system to recognize that specific cancer if it returns."

Epic

Description: Dominant EHR vendor.
Why mentioned: Benchmark for OpenEvidence's adoption.
Quotes: "Epic, which has been in the market for nearly 50 years, sits at 44%."

Penda Health, Boston Children's, CHOP / Penn

Description: Providers in AI and gene-therapy case studies.
Why mentioned: Real-world validation of OpenAI's clinical copilot and of N-of-1 gene editing.
Quotes: "Doctors at CHOP and Penn sequenced his genome and designed a custom gene-editing therapy for his liver."

Thrive Capital

Description: Investment firm with $65B+ AUM; raised Thrive X at over $10B in 2026.
Why mentioned: The subject of the interview.
Quotes: "Thrive has invested in healthcare since its founding and has put $1B+ into the sector." / "The firm has incubated around 10 healthcare companies, and most of them, including Oscar, Cedar, Rightway and Cadence, are valued at over $1B."

4. People Identified

Dr. Nworah Ayogu

Description: Thrive Capital partner; board-certified internist; former Cityblock founding team member, Amazon Clinic GM and first CMO of Amazon Pharmacy.
Why mentioned: Interview subject leading Thrive's healthcare investing.
Quotes: "He joined Thrive in 2024 to lead healthcare investing." / "My clinician hat is what let me actually see, oh wow, this is a differentiated product."

Josh Kushner

Description: Thrive founder; Oscar Health co-founder.
Why mentioned: Oscar was Thrive's first investment.
Quotes: "Josh Kushner co-founded Oscar Health when he founded Thrive Capital, and Oscar was the firm's first investment."

Demis Hassabis

Description: Nobel laureate; founder of Isomorphic Labs.
Why mentioned: Leads the AI drug design effort Thrive backed.
Quotes: "Isomorphic Labs, founded by Nobel laureate Demis Hassabis, is building AI models to compress that process."

Daniel Nadler

Description: OpenEvidence founder.
Why mentioned: Thrive invested the day Ayogu met him.
Quotes: "Ayogu drove to founder Daniel Nadler's home in Malibu, and Thrive invested that day."

Mario Schlosser

Description: Oscar co-founder, now CTO.
Why mentioned: Walked Ayogu through Oscar as a medical student; shifted to technology focus.
Quotes: "CEO Mark Bertolini, former CEO of Aetna, joined while Schlosser moved to CTO to focus on technology."

Mark Bertolini

Description: Oscar CEO; former Aetna CEO.
Why mentioned: Leads Oscar's current growth phase.
Quotes: "CEO Mark Bertolini, former CEO of Aetna, joined."

DJ Seo

Description: Neuralink president.
Why mentioned: Leads much of the company.
Quotes: "President DJ Seo leads much of the company."

Matt de Jonge

Description: Fortell founder; former Butterfly Network hardware engineer.
Why mentioned: Built the custom chip behind Fortell's hearing aid.
Quotes: "Fortell, founded by former Butterfly Network hardware engineer Matt de Jonge, built a custom chip taped out at TSMC."

Kareem Zaki

Description: Thrive colleague and longtime friend of Ayogu.
Why mentioned: Part of Ayogu's path to Thrive.
Quotes: "He has known Kushner and Kareem Zaki since college."

Molly O'Shea

Description: Host of Sourcery.
Why mentioned: Interviewer and author.
Quotes: "Dr. Nworah Ayogu, MD, MBA, Partner at Thrive Capital, joins Sourcery to discuss how AI is transforming drug discovery, medicine, and the economics of healthcare."

Steve Martin and Henry Kravis

Description: Notable Fortell users.
Why mentioned: Social proof for the hearing aid.
Quotes: "Steve Martin and Henry Kravis are users."

5. Operating Insights

Test the product like a customer before you underwrite it

Ayogu's conviction came from direct use: he tested OpenAI's reasoning models on weekly NEJM case studies, and tested OpenEvidence himself before driving to the founder's home. His practitioner view was decisive:

"My clinician hat is what let me actually see, oh wow, this is a differentiated product."

Recruit a dual-discipline team and integrate it deliberately

The "bilingual" model requires both sides to be best-in-class, then operationally merged. Isomorphic calls its integration approach "the Iso way," and Neuralink insources capabilities like pathology, radiology and battery engineering.

"People who are truly N of 1 want to work with other N of 1 people."

Build trust through hard outcomes, and design for the hours outside the clinic

Measure on clinical outcomes, not just experience:

"Patient experience matters, but these are hard outcomes in terms of you being in the hospital. Is your blood pressure controlled? What's your A1C? Are you having less strokes?"

Cadence's design logic: a patient "spends at most a few hours in the office and more than 8,000 hours outside it." Operational tactics like "calling patients the moment a reading comes in has raised reach rates 70%," and AI medication-titration agents that "match prescriber decisions 98% of the time."

6. Overlooked Insights

Hearing loss is a dementia lever, not just a quality-of-life issue

"Hearing loss affects 1.5B people worldwide and is the largest modifiable risk factor for dementia. People with hearing loss have about a one-third higher likelihood of dementia." This reframes hearing aids like Fortell's as preventive neurological care with a large addressable population, and Fortell still scales manually: it "runs a waitlist and fits patients in person at its New York office while it scales production."

Surgeon capacity is a hidden, AI-addressable constraint

"Surgeons spend about half their time on non-operative cases, and LA patients wait 3 to 4 months to see an orthopedic surgeon. If AI triages demand, wait times shorten and surgeons spend more of their time operating." Ayogu's related framing, "we need a 10X nurse a lot more than we need a 10X engineer," points to labor-capacity amplification in a system facing an 86,000-doctor shortage as an underappreciated opportunity area.